Title:
USE OF CDK16 AS TARGET IN PREPARATION OF MEDICINE FOR TREATING TRIPLE-NEGATIVE BREAST CANCER
Document Type and Number:
WIPO Patent Application WO/2023/142978
Kind Code:
A1
Abstract:
The present disclosure provides use of CDK16 as a target in the preparation of a medicine for treating triple-negative breast cancer (TNBC). According to the present disclosure, research has found that the knock-down of the CDK16 can significantly inhibit the growth of TNBC xenograft tumors, PDX and PDO, and the mechanism is mainly the inhibition of phosphorylation of PRC1 (T481) and prevention of spindle apparatus formation during cell mitosis by means of the knock-down of the CDK16, which prevents the cells from dividing normally and thus inhibits the occurrence, development and metastasis of the TNBC tumors. Additionally, research has found that the covalent small-molecule inhibitor Rebastinib of the CDK16 shows a good effect in inhibiting the development of TNBC tumors, and is a potential novel medicine for treating the TNBC.
Inventors:
VASILEVICH NATALIA (CN)
SUN LICHUN (CN)
TIAN YUAN (CN)
CAI CHEGUO (CN)
ZHANG MENGNA (CN)
LI XIAO (CN)
YU LIYA (CN)
ZHANG LINGXIAN (CN)
SUN LICHUN (CN)
TIAN YUAN (CN)
CAI CHEGUO (CN)
ZHANG MENGNA (CN)
LI XIAO (CN)
YU LIYA (CN)
ZHANG LINGXIAN (CN)
Application Number:
PCT/CN2023/071088
Publication Date:
August 03, 2023
Filing Date:
January 06, 2023
Export Citation:
Assignee:
SHENZHEN TYERCAN BIO PHARM CO LTD (CN)
International Classes:
A61K31/4709; A61K45/00; A61K31/7088; A61P35/00; A61P35/04
Foreign References:
| CN114452391A | 2022-05-10 | |||
| CN106822128A | 2017-06-13 | |||
| CN109310768A | 2019-02-05 | |||
| CN112367991A | 2021-02-12 |
Other References:
DIXON-CLARKE SARAH E., SHEHATA SAIFELDIN N., KROJER TOBIAS, SHARPE TIMOTHY D., VON DELFT FRANK, SAKAMOTO KEI, BULLOCK ALEX N.: "Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16", BIOCHEMICAL JOURNAL, PUBLISHED BY PORTLAND PRESS ON BEHALF OF THE BIOCHEMICAL SOCIETY., GB, vol. 474, no. 5, 1 March 2017 (2017-03-01), GB , pages 699 - 713, XP093082226, ISSN: 0264-6021, DOI: 10.1042/BCJ20160941
Attorney, Agent or Firm:
CHOFN INTELLECTUAL PROPERTY (CN)
Download PDF: